This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
Patients who have completed the 52-week treatment duration in Study A19-201 and are considered by the investigator or sub investigator to be eligible for participation in this study
Patients who have given written informed consent to participate in this study
Patients who are considered by the investigator or sub investigator to be ineligible for continued treatment with P1101